References
Corsello CM. Early intervention in autism. Infants Young Child 2005; 18: 74–85
Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association, 2000
Chavez B, Chavez-Brown M, Sopko Jr MA, et al. Atypical anti-psychotics in children with pervasive developmental disorders. Pediatr Drugs 2007; 9(4): 249–66
Griffith EM, Pennington BF, Wehner EA, et al. Executive function in young children with autism. Child Dev 1999; 70: 817–32
Happe F, Ronald A, Plomin R. Time to give up on a single explanation for autism. Nat Neurosc 2006; 9: 1218–20
National Institutes of Health. ’Autism fact sheet’ NINDS. Bethesda (MD): (National Institutes of Health, 2006 Apr. NIH publication no. 06-1877
Malone RP, Gratz, SS, Delaney MA, et al. Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders. CNS Drugs 2005; 19(11): 923–34
National Institute of Neurological Disorders and Stroke. NINDS pervasive development disorders information page [online]. Available from URL: http://www.ninds.nih.gov [Accessed 2008 Jan 29]
Smith T. Outcome of early intervention for children with autism. Clin Psychol Sci Pract 1999; 6: 33–49
Jensen VK, Sinclair LV. Treatment of autism in young children: behavioral intervention and applied behavioral analysis. Infants Young Child 2002; 14: 42–52
Chavez B, Chavez-Brown M, Rey JA. Role of risperidone in children with autism spectrum disorder. Ann Pharmacother 2006; 40: 909–16
American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601
Rights and permissions
About this article
Cite this article
Atypical antipsychotics may be an appropriate option to alleviate behavioural symptoms in some children with pervasive developmental disorders. Drugs Ther. Perspect 24, 17–20 (2008). https://doi.org/10.2165/00042310-200824060-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200824060-00005